ACRS
Price
$1.56
Change
-$0.07 (-4.29%)
Updated
Jun 26 closing price
Capitalization
168.92M
40 days until earnings call
MYNZ
Price
$1.41
Change
-$0.04 (-2.78%)
Updated
Jun 26, 04:59 PM (EDT)
Capitalization
20.77M
68 days until earnings call
Interact to see
Advertisement

ACRS vs MYNZ

Header iconACRS vs MYNZ Comparison
Open Charts ACRS vs MYNZBanner chart's image
Aclaris Therapeutics
Price$1.56
Change-$0.07 (-4.29%)
Volume$994.06K
Capitalization168.92M
Mainz Biomed
Price$1.41
Change-$0.04 (-2.78%)
Volume$4.8K
Capitalization20.77M
ACRS vs MYNZ Comparison Chart in %
Loading...
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYNZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACRS vs. MYNZ commentary
Jun 27, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACRS is a Buy and MYNZ is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 27, 2025
Stock price -- (ACRS: $1.56 vs. MYNZ: $1.40)
Brand notoriety: ACRS and MYNZ are both not notable
ACRS represents the Biotechnology, while MYNZ is part of the Medical Specialties industry
Current volume relative to the 65-day Moving Average: ACRS: 133% vs. MYNZ: 52%
Market capitalization -- ACRS: $168.92M vs. MYNZ: $20.77M
ACRS [@Biotechnology] is valued at $168.92M. MYNZ’s [@Medical Specialties] market capitalization is $20.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $301.01B to $0. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B. The average market capitalization across the [@Medical Specialties] industry is $8.56B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACRS’s FA Score shows that 1 FA rating(s) are green whileMYNZ’s FA Score has 1 green FA rating(s).

  • ACRS’s FA Score: 1 green, 4 red.
  • MYNZ’s FA Score: 1 green, 4 red.
According to our system of comparison, ACRS is a better buy in the long-term than MYNZ.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACRS’s TA Score shows that 5 TA indicator(s) are bullish while MYNZ’s TA Score has 4 bullish TA indicator(s).

  • ACRS’s TA Score: 5 bullish, 5 bearish.
  • MYNZ’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both ACRS and MYNZ are a good buy in the short-term.

Price Growth

ACRS (@Biotechnology) experienced а +9.86% price change this week, while MYNZ (@Medical Specialties) price change was -8.50% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +3.59%. For the same industry, the average monthly price growth was +34.25%, and the average quarterly price growth was +14.95%.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.93%. For the same industry, the average monthly price growth was +0.51%, and the average quarterly price growth was +0.02%.

Reported Earning Dates

ACRS is expected to report earnings on Aug 06, 2025.

MYNZ is expected to report earnings on Sep 03, 2025.

Industries' Descriptions

@Biotechnology (+3.59% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Medical Specialties (+0.93% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACRS($169M) has a higher market cap than MYNZ($20.8M). ACRS YTD gains are higher at: -37.097 vs. MYNZ (-67.593). MYNZ has higher annual earnings (EBITDA): -27.15M vs. ACRS (-53.49M). ACRS has more cash in the bank: 105M vs. MYNZ (9.32M). ACRS has higher revenues than MYNZ: ACRS (17.8M) vs MYNZ (874K).
ACRSMYNZACRS / MYNZ
Capitalization169M20.8M813%
EBITDA-53.49M-27.15M197%
Gain YTD-37.097-67.59355%
P/E RatioN/AN/A-
Revenue17.8M874K2,037%
Total Cash105M9.32M1,127%
Total DebtN/A10.2M-
FUNDAMENTALS RATINGS
ACRS: Fundamental Ratings
ACRS
OUTLOOK RATING
1..100
77
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
PROFIT vs RISK RATING
1..100
98
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
46
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
10

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ACRSMYNZ
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
83%
Bullish Trend 2 days ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
81%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 10 days ago
85%
Bearish Trend 4 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
88%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ACRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MYNZ
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JIVCX29.58N/A
N/A
JPMorgan U.S. Applied Data Sci Val C
IGHSX12.13N/A
N/A
Voya Global High Dividend Low Vol Port S
NUIAX30.87N/A
N/A
Nuveen International Dividend Growth A
JDICX15.94N/A
N/A
JHancock Disciplined Value Intl C
TAAHX34.85N/A
N/A
Transamerica Multi-Managed Balanced R